SST2-positive neuroendocrine neoplasms

Clinical trials for SST2-positive neuroendocrine neoplasms explained in plain language.

Never miss a new study

Get alerted when new SST2-positive neuroendocrine neoplasms trials appear

Sign up with your email to follow new studies for SST2-positive neuroendocrine neoplasms, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New targeted drug trial opens for patients with Hard-to-Treat neuroendocrine cancers

Disease control Recruiting now

This study tests a new drug called CRN09682 in people with progressive metastatic neuroendocrine neoplasms and other solid tumors that have a specific marker (SST2). The trial has two phases: first, finding the safest dose, then testing that dose in more patients. About 150 parti…

Matched conditions: SST2-POSITIVE NEUROENDOCRINE NEOPLASMS

Phase 1/2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control

Last updated Aug 02, 2026 00:00 UTC

SST2-positive neuroendocrine neoplasms

Get alerted when new SST2-positive neuroendocrine neoplasms trials appear

New targeted drug trial opens for patients with Hard-to-Treat neuroendocrine cancers